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Background/Aim: Several studies have documented the effects of isothiocyanates (ITCs) on 
cancer prevention by inducing oxidative stress, activating apoptosis, affecting cell cycle 
regulation, etc. Previously, we have shown that ITCs, administered at low concentrations by 
the means of double-bolus are capable of potentiating cytotoxicity in human malignant 
melanoma (A375) cells by inducing apoptosis. The aim of the present study was to further 
investigate the effect of the treatment of A375 cells with ITCs on cell cycle progression and 
the levels of various cell cycle regulators. Materials and Methods: Cell cycle analysis was 
performed by means of flow cytometry whereas western immunoblotting was used to 
determine the expression levels of these protein regulators. Results: Our data showed an 
increase in the number of cells in the G2/M phase accompanied by a decrease in the G0/G1 
phase, while several cell-cycle regulators were shown to be differentially expressed upon 
exposure to ITCs.  
Conclusion: ITCs induced cell cycle arrest in A375 cells. 
 
Malignant melanoma is the most aggressive and lethal form of skin cancer due to its high 
mortality and continuously increasing incidence rates (1, 2). On the other hand, consumption 
of cruciferous vegetables has been suggested to play a beneficial role in cancer prevention. 
Their anti-cancer effects appear to be attributed to isothiocyanates (ITCs), a group of 
compounds derived from the hydrolysis of glucosinolates (GSLs) which are sulfur- and 
nitrogen-containing glycosides, by the enzyme myrosinase (3-6). In recent years, various 
studies have focused on investigating the diverse pathways induced by ITCs including (i) 
activation of phase I and II detoxification, (ii) generation of oxidative stress, (iii) induction of 
cell cycle growth arrest and apoptosis, (iv) inhibition of tumor cell invasion, metastasis and 
angiogenesis, (v) suppression of inflammatory response and (vi) regulation of epigenetic 
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cascades (7-11). To this end, we have previously published on the ability of different ITCs (e.g. 
sulforaphane, SFN; phenethyl isothiocyanate, PEITC; and benzyl isothiocyanate, BITC) to 
trigger apoptosis in human malignant melanoma (A375) cells by utilizing a previously 
published means of administering low concentrations of ITCs as a refreshed double-bolus (12). 
This study aimed to investigate further the effects of ITCs on the cell cycle, as an additional 
mechanism contributing to the cytotoxicity observed in our previous study in A375 cells. 
 
Materials and Methods  
Chemicals and reagents 
Dulbecco Modified Eagle Media (DMEM), Phosphate Buffer Saline (PBS), Fetal Bovine 
Serum (FBS), trypsin, penicillin/streptomycin and L-glutamine were obtained from Labtech 
(Sussex, UK). Bovine Serum Albumin (BSA) was purchased from Biosera (Boussens, France). 
Polyvinylidene Difluoride (PVDF) membranes, page ruler plus protein marker, ECL and 
FxCycle PI/RNase staining solution were supplied by Thermo Fisher Scientific (Waltham, 
MA, USA). All primary and horseradish peroxidase-conjugated secondary antibodies were 
purchased from Cell Signaling (Danvers, MA, USA) apart from β-actin (Sigma-Aldrich; St. 
Louis, MO, USA). SFN was purchased from Abcam (Cambridge, UK) while PEITC and BITC 
from Sigma-Aldrich (St. Louis, MO, USA). Stock solutions were prepared in DMSO (Sigma-
Aldrich; St. Louis, MO, USA) at 100 mM and stored at -20oC. All chemicals were of analytical 
grade and obtained from Invitrogen (Carlsbad, CA, USA), Applichem (Darmstadt, Germany) 
and Sigma-Aldrich. 
 
Cell lines and treatments with isothiocyanates 
The A375 cell line was purchased from Sigma-Aldrich and maintained in high glucose DMEM 
supplemented with 10% FBS, 2mM L-glutamine and 1% pen/strep (100 U/ml penicillin, 100 
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μg/ml streptomycin). Cells were cultured in a humidified atmosphere at 37oC and 5% CO2. 
They were grown as monolayer cultures and sub-cultured when reaching 80-90% confluence. 
SFN, PEITC and BITC were added twice as a refreshed bolus concentration of 5 μM (each 
added at t0 and refreshed after 24 h) over a 48-h incubation period. 
 
Protein extraction and quantification 
Cells were treated with 5 μM of ITC or vehicle (for 48 h), harvested via trypsinization, washed 
twice with cold PBS and then stored at -20oC. Cell pellets were lysed in lysis buffer (10mM 
HEPES pH 7.9, 10mM KCl, 0.1mM EDTA, 1.5mM MgCl2, 0.2% NP-40) supplemented with 
protease inhibitors. Samples were incubated on ice while periodically vortexed over a 30 min 
period. Cell lysates were centrifuged (14,000 x g) at 4oC for 15 min and supernatants were 
collected. Protein concentration was determined by the BCA assay (Thermo Fisher Scientific) 
according to the manufacturer’s protocol. Protein extracts were stored at -20oC until usage. 
 
Western immunoblotting 
Proteins (40 μg) were separated by using gradient SDS-polyacrylamide gels (8-20%) and then 
were transferred onto either 0.2 or 0.45 μm PVDF membranes (depending on their molecular 
weight) by wet transfer (in 1X transfer buffer) at predetermined running conditions. The blots 
were blocked with 5% (w/v) non-fat milk powder in Tris Buffered Saline, with Tween 20 
(TBST) buffer, for 1 h at room temperature (RT) and then incubated with specific primary 
antibodies (overnight at 4oC) under gentle agitation. Next day, the blots were washed (three 
times) in TBST buffer for 10 min and then incubated with an appropriate secondary antibody 
(for 1 h at RT) under agitation. Blots were incubated with the super signal west pico 
chemiluminescent substrate (Thermo Fisher Scientific) according to the manufacturer’s 
instructions before being imaged by using a ChemiDoc XRS+ system (Bio-Rad, Perth, UK).  
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Cell cycle analysis by flow cytometry 
Cells were treated with 5 μM of ITC or vehicle (for 48 h), harvested via trypsinization and 
washed twice with PBS. Then, cells (0.5 x 106) were fixed in cold 70% ethanol (for 1 h) at 4oC 
until further processed. Cells were washed twice with PBS to remove ethanol, and then were 
suspended in FxCycle PI/RNase staining solution for 30 min (at RT) in dark. Samples were 
analyzed by FACS Calibur Flow Cytometer (BD Biosciences,) with 10,000 events being 
recorded under each condition and analyzed using the FlowJo V10 software (BD Biosciences). 
 
Statistical analysis 
Statistical analyses were performed by one-way ANOVA with Tukey’s test for multiple 
comparisons after using the SPSS v.22 software. Statistical significance was set at p<0.05. 
 
Results 
Human malignant melanoma (A375) cells were exposed to a refreshed, double-bolus low 
concentration (5 µM) of SFN, PEITC or BITC according to our previous findings (12). 
Determination of the distribution of cells to cell cycle phases by flow cytometry, revealed an 
induction of the G2/M cell cycle phase by all ITCs (Figure 1A, B). Exposure to BITC induced 
the highest increase in the number of cells in the G2/M phase followed by SFN and PEITC 
which had the same effect. This pattern was followed by a reduction in the number of cells in 
the G0/G1 phase, by all three ITCs, while only BITC induced a significant change in the 
number of cells in the S phase of the cell cycle (Figure 1A, B). Finally, our data showed a 
profound elevation, to a variable degree, in the percentage of cells in the sub-G1 phase (which 
accounts for a necrotic and/or apoptotic cell population) by all three ITCs (Figure 1A, B). The 
underlying mechanism(s) contributing to the observed induction of cell cycle growth arrest in 
A375 cells was examined by monitoring alterations in expression levels of various cell cycle 
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protein regulators. According to our results, the levels of cyclin dependent kinase inhibitors 
p21 and p27 as well as phospho-p53 (Ser15) were up-regulated in contrast to those of p18 
which were markedly reduced (Figure 2A). Furthermore, the levels of cyclins D1 and D3 were 
increased independently of the type of ITC utilized (Figure 2B). In addition, cyclin-dependent 
kinase 6 (CDK6) was shown to decrease while cyclin-dependent kinase 2 (CDK2) significantly 
increased in response to ITCs exposure. Finally, the protein expression levels of cyclin-
dependent kinase 4 (CDK4) were shown to be up-regulated, in the case of SFN and PEITC, as 
opposed to exposure to BITC, which caused a marked reduction (Figure 2C). Overall, our data 
highlight the involvement of various cell cycle-regulating proteins in inducing cell cycle arrest 
as a consequence of the exposure of A375 cells to low-ITC concentrations administered as 
refreshed, double-bolus (12). 
 
Discussion 
Our findings revealed an increase in the number of cells in the G2/M phase accompanied by a 
decrease in the number of cells in the G0/G1 phase following exposure of A375 cells to ITCs. 
Furthermore, a reduction in the S phase population was also observed but only after BITC 
exposure. Moreover, in agreement with our previous findings of ITC-induced apoptosis in 
A375 cells, a profound elevation in the percentage of cells in the sub-G1 phase fraction was 
detected (12, 13). However, it is of significance to note that the levels of cytotoxicity were 
comparable with those in other experimental platforms using rather higher concentrations of 
ITCs, administered as a single bolus (14-18). In order to study the mechanism of action of 
ITCs, the expression levels of various cell cycle regulators were examined. Treatment with 
ITCs resulted in an induction of p21 and p27 expression levels, a finding consistent with the 
role of both proteins in binding to cyclin-CDK complexes and thus suppressing cell cycle 
progression (19). In support, several studies have demonstrated the ITC-induced up-regulation 
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of p21 in various human cancer cell lines (20, 21). Similarly, increased p27 expression has 
been documented in both in vitro and in vivo models treated with various ITCs (22, 23). In 
addition, the levels of phospho-p53 (Ser15) protein were also found to be upregulated. This 
finding is in accordance with the findings of other studies showing that ITC-induced apoptosis 
is associated with p53 up-regulation in melanoma cells (16, 24). On the contrary, a reduction 
in p18 levels (more evident in BITC exposure) was observed. This effect can be attributed to 
the interaction of this protein with CDK4 and CDK6 resulting in their inhibition and 
consequently cell cycle halt (25). Furthermore, increased levels of CDK2 (under exposure to 
each ITC) were also observed suggesting its interaction with cyclin E which may lead to cell 
cycle progression and/or apoptotic induction (26, 27). Finally, when examining expression 
levels of cyclins D1 and D3, it was apparent that both proteins were up-regulated in response 
to each ITC exposure. These findings are also consistent with those of other studies where 
exposure of melanoma cells to ITCs was shown to be associated with the constitutive activation 
of the BRAF-MEK-ERK1/2 cascade as well as cell cycle progression (28, 29). Overall, the 
present study provides further evidence in support of our previously published means of 
treatment with ITCs in the context of halting cell cycle progression by affecting the expression 
of several cell cycle regulators in human malignant melanoma (A375) cells. These 
observations, along with our previously published apoptotic induction, highlight the 
importance of this novel means of delivering low-ITC concentrations as refreshed, double-
bolus as a more efficient and potent therapeutic strategy against malignant melanoma. 
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Figure Legends 
Figure 1. The effect of ITCs exposure on the distribution of human malignant melanoma 
(A375) cells in cell cycle phases. (A) Representative histograms of the distribution of cells in 
cell cycle phases following exposure to 5μM of SFN, PEITC or BITC for an initial 24 h after 
which exposures were refreshed for a further 24h incubation (for a total exposure period of 48 
h). (B) Diagram showing the distribution of cells in sub-G1, G0/G1, S, G2/M cell cycle phases 
and polyploidy. Results are expressed as percentage of total cells and mean ± SD were 
calculated. Asterisk (*) indicates statistical significance at p<0.05 when compared to control. 
Brackets denote comparisons between each cell cycle phase under each individual ITC 
exposure. 
 
Figure 2. The effect of ITCs on the levels of various cell cycle regulators in human malignant 
melanoma (A375) cells.  A375 cells were exposed to 5 μM of SFN, PEITC or BITC for an 
initial 24 h after which exposures were refreshed for a further 24 h incubation (for a total 
exposure period of 48 h). Cell extracts were analysed by western blot using antibodies against 
p18, p21, p27 and phospho-p53 (Ser15) (A), cyclins D1 and D3 (B) and cyclin dependent 
kinases 2, 4, and 6 (C) β-actin was used as a loading control. 
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